FAST Starts GeneTx Biotherapeutics to Speed Development of Antisense Therapy for Angelman
FAST has started a for-profit company to try to accelerate the development of a potential cutting-edge treatment for Angelman syndrome. GTX-101 is an antisense therapy that works to silence gene expression by binding to the RNA the gene produces. Gene expression is the process by which information from a gene…